(function(){ var content_array=["

参考文献<\/span><\/p> \n

[1] Clinical Trials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04059094?term=BI+1265162&rank=1<\/a>. [Last accessed October 2019<\/span>].
[2] Boehringer Ingelheim. Data on file. 2019.
[3] EU Clinical Trials Register. Available at: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000261-21\/FR<\/a> [Last accessed October 2019<\/span>]
[4] ECFS Clinical Trial Network. Available at: https:\/\/www.ecfs.eu\/boehringer-1399-0003.<\/a> [Last accessed October 2019<\/span>].
[5] Cystic Fibrosis Trust. What is cystic fibrosis? Available at: https:\/\/www.cysticfibrosis.org.uk\/what-is-cystic-fibrosis<\/a>. [Last accessed October 2019<\/span>].
[6] Cystic Fibrosis Foundation. About Cystic Fibrosis. Available at: https:\/\/www.cff.org\/What-is-CF\/About-Cystic-Fibrosis\/<\/a>. [Last accessed October 2019<\/span>].
[7] Althaus M. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art. Curr Mol Pharmacol<\/i>. 2013 Mar;6(1):3–12. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23547930<\/a>. [Last accessed October 2019<\/span>].
[8] Cystic Fibrosis Foundation. Drug Development Pipeline. Available at: https:\/\/www.cff.org\/Trials\/Pipeline\/details\/10164\/BI-1265162<\/a> [Last accessed September 2019<\/span>].
[9] Mall M.A., et al. Targeting ion channels in cystic fibrosis. J Cystic Fibrosis. 2015;14(5):561–570.
[10] Zierenberg, B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(suppl 1):S19–S24.
[11] Dalby R, et al. A review of the development of Respimat® Soft MistTM Inhaler. Int J Pharm. 2004;283(1–2):1-9.
[12] Olufunmilola A, Morris A. Opportunities for Outpatient Pharmacy Services for Patients with Cystic Fibrosis: Perceptions of Healthcare Team Members. Pharmacy (Basel<\/span>).<\/i> 2019 Jun; 7(2): 34. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6631244\/<\/a>. [Last accessed October 2019]. <\/p>"]; $("#dvExtra").html(content_array[0]);})();